DOCSLIB.ORG

Summary of COVID-19 Vaccine Candidates and Related Agreements

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summary of COVID-19 Vaccine Candidates and Related Agreements Summary of COVID-19 vaccine candidates and related agreements This table tracks various development, production, supply, funding, and intellectual property agreements for COVID-19 vaccine candidates. The information included in the table was sourced from publicly available information such as company websites and reputable news sources. In addition, the WHO Draft Landscape of COVID-19 Candidate Vaccines was used as a central reference point to identify new vaccine candidates. Please note: the contents of this table are formed from GHIAA’s understanding and interpretation of publicly available information. The purpose of this table is to begin to identify agreements related to the COVID-19 response, however it should not be relied upon to provide a complete overview of the current landscape. Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology AZD1222 (previously Jenner Institute, University Phase 3 clinical trial UK Government Supply agreement between AstraZeneca & Inclusive ChAdOx1) of Oxford (academic (government) Vaccines Alliance Non-Replicating Viral Vector institution) ISRCTN Registry Identifier: University of Oxford ISRCTN89951424 (Phase 3) Licensing, manufacturing, and distribution agreement AstraZeneca (multinational (academic institution) between R-Pharm and AstraZeneca pharmaceutical company) ClinicalTrials.gov Identifiers BARDA (government) Serum Institute of India (U.S.): Supply agreement between Symbiosis CEPI (funder) (vaccine manufacturer) NCT04456595 (Phase 3) Pharmaceutical and AstraZeneca NCT04352608 (Phase 1/2) Gavi, the Vaccine IQVIA (contract research NCT04383574 (Phase 1/2) Alliance (multilateral Supply agreement for 300 million doses between U.S. organization) organization) Government and AstraZeneca EU Clinical Trials Register Identifier: 2020-001228-32 Supply agreement for100 million doses (30 million by (Phase 2b/3) Sept. 2020) between U.K. Government and 2020-001072-15 (Phase AstraZeneca 1/2) Supply/manufacturing agreement between Brazilian Pan African Clinical Trials Government and AstraZeneca Registry Identifier: PACTR202006922165132 Manufacturing agreement between AstraZeneca & (Phase 1/2) Catalent Supply & licensing agreement between Serum Institute of India and AstraZeneca Manufacturing agreement for clinical trials between Serum Institute of India and AstraZeneca Researched by: Nathan Gardner 1 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Manufacturing, procurement and distribution agreement for 300 million doses between CEPI, Gavi, and AstraZeneca Manufacturing agreement (1-year) between Oxford Biomedica & AstraZeneca Funding partnership between BARDA and AstraZeneca Funding partnership between CEPI, Gavi, and AstraZeneca Development agreement between Oxford & AstraZeneca Development collaboration between IQVIA & AstraZeneca mRNA-1273 Moderna (biotechnology Phase 3 clinical trial NIAID (government) 10-year strategic collaboration agreement between LNP-encapsulated mRNA company) Moderna & Lonza BARDA (government) ClinicalTrials.gov Identifiers Lonza (multinational (U.S.): CEPI (funder) Funding partnership between Moderna & CEPI pharmaceutical company) NCT04283461 (Phase 1) Operation Warp Speed NIAID (government) NCT04405076 (Phase 2) Funding partnership between Moderna & BARDA (government) NCT04470427 (Phase 3) Manufacturing agreement between Moderna & Laboratorios Farmacéuticos Rovi Inactivated vaccine Wuhan Institute of Phase 3 clinical trial Biological Products (state- owned biotechnology Chinese Clinical Trials company) Registry Identifiers: ChiCTR2000031809 (Phase Sinopharm (state-owned 1/2) biotechnology company) Researched by: Nathan Gardner 2 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology ChiCTR2000034780 (Phase 3) Inactivated vaccine Beijing Institute of Biological Phase 3 clinical trial Products (state-owned biotechnology company) Chinese Clinical Trials Registry Identifier: Sinopharm (state-owned ChiCTR2000032459 (Phase biotechnology company) 1/2) ChiCTR2000034780 (Phase 3) CoronaVac Sinovac (state-owned Phase 3 clinical trial Advantech Capital Development agreement between Sinovac & Instituto Inactivated + alum biotechnology company) (general industry) Butatan ClinicalTrials.gov Identifiers Instituto Butatan (research Vivo Capital (general (U.S.): Clinical trial and manufacturing agreement between institute) industry) NCT04456595 (Phase 3) Sinovac & PT BioFarma NCT04352608 (Phase 1/2) Government of China NCT04383574 (Phase 1/2) (government) Bacillus Calmette-Guerin University of Melbourne Phase 2/3 clinical trial Gates Foundation Funding agreement between Gates and University of (BCG) live-attenuated vaccine (academic institution) (funder) Melbourne ClinicalTrials.gov Identifiers Murdoch Children’s Sarah and Lachlan (U.S.): Research Institute (research Murdoch (funder) NCT04327206, institute) NCT04328441 The Royal Children’s Radboud University Medical Hospital Foundation Center (non-profit) (non-profit) Faustman Lab at The Minderoo Massachusetts General Foundation (non-profit) Hospital (research institute) South Australian government (funder) NAB Foundation (non- profit) Researched by: Nathan Gardner 3 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Calvert-Jones Foundation (non-profit / funder) HUG Foundation (non- profit / funder) River Capital (general industry) Individual donors BNT162b2 Pfizer (multinational Phase 2/3 clinical trial Material transfer and Collaboration agreement LNP-mRNA pharmaceutical company) between Pfizer & BioNTech EU Clinical Trials Register BioNTech (biotechnology Identifier: 2020-001038-36 Licensing & equity investment agreement between company) (Phase 1/2) Fosun and BioNTech Fosun Pharma (multinational ClinicalTrials.gov Identifier Supply agreement for 100 million doses between U.S. pharmaceutical company) (U.S.): NCT04368728 (Phase Government, Pfizer & BioNTech 1/2) Supply agreement for 120 million doses between Chinese Clinical Trial Government of Japan, Pfizer, & BioNTech Registry Identifier: ChiCTR2000034825 (Phase Clinical trial agreement between Pfizer, BioNTech, 1/2) The University of Rochester Medical Center and Rochester Regional Health Adjuvanted recombinant Anhui Zhifei Longcom Phase 2 clinical trial Development partnership between Anhui Zhifei protein (RBD-Dimer) Biopharmaceutical Longcom Biopharmaceutical & Institute of Protein Subunit (biotechnology company) ClinicalTrials.gov Identifier Microbiology, Chinese Academy of Sciences (U.S.): Institute of Microbiology, NCT04445194 (Phase 1) Chinese Academy of NCT04466085 (Phase 2) Sciences (academic institution) Researched by: Nathan Gardner 4 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Ad5-nCoV CanSino Biologics Phase 2 clinical trial Development agreement between National Research Adenovirus Type 5 Vector, (biotechnology company / Council Canada & CanSino Biologics Non-Replicating Viral Vector vaccine manufacturer) Chinese Clinical Trial Registry Identifiers: Development agreement between Sartorius, Beijing Beijing Institute of ChiCTR2000030906 (Phase Institute of Biotechnology & CanSino Biologics Biotechnology (academic 1), ChiCTR2000031781 institution) (Phase 2) 2014 Licensing agreement (between CanSino and National Research Council Canada – for cell line) ClinicalTrials.gov Identifier (U.S.): NCT04313127 NVX-CoV2373 Novavax (biotechnology Phase 1/2 clinical trial Operation Warp Speed Manufacturing agreement between AGC Biologics & Full length recombinant SARs company) (government) Novavax CoV-2 glycoprotein ClinicalTrials.gov Identifier CEPI (funder) nanoparticle vaccine (U.S.): Funding agreement between Novavax and the U.S. adjuvanted with Matrix M – NCT04368988 (Phase 1/2) U.S. Department of Department of Defense Protein Subunit Defense (government) Funding agreement between Novavax and CEPI Funding agreement including the delivery of 100 million doses starting late 2020 between Operation Warp Speed and Novavax Contract development and manufacturing agreement between Emergent & Novavax Phase 1 clinical trial agreement between Nucleus & Novavax ZyCoV-D: DNA plasmid Cadila Healthcare Limited Phase 1/2 clinical trial vaccine (multinational pharmaceutical company) Chinese Clinical Trial Registry Identifier: Researched by: Nathan Gardner 5 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology CTRI/2020/07/026352 (Phase 1/2) DNA plasmid vaccine Osaka University (academic Phase 1/2 clinical trial Collaboration between Osaka University, AnGes & institution) Takara Bio Japanese Clinical Trial AnGes (biotechnology Identifier: Manufacturing agreement between Cytiva & Takara company) JapicCTI-205328 (Phase I) Bio Takara Bio (biotechnology company) ClinicalTrials.gov Identifier (U.S.): NCT04463472 (Phase 1/2) Inactivated vaccine Institute of Medical Biology, Phase 1/2 clinical trial Jack Ma Foundation Chinese Academy of (funder) Medical Sciences (academic ClinicalTrials.gov Identifiers institution) (U.S.): NCT04412538 (Phase I) NCT04470609 (Phase 1/2) RBD-based vaccine Kentucky Bioprocessing,
Load more

Recommended publications
  • Old Road Campus
    Old Road Campus 4a, 4b, 4c, U5 n o t Oxford City Centre g OLD ROAD n i d 4a, 4b, 4c, U5 a e H K O L L A D R O W AD E M I L 4,4a,4b,4c, U1X,U5 A41 42 4,4a,4b,4c,U5 Rin D 4 g R oad 6 7 1 13 3 11 C H U R C H I L L 900 D 2 R I 700, 900 V E E O x f o 5 A C rd 12 C i ty 10 C e n t re B 8 CAR PARK C 9 h u r c R F h i O l l O S H E o V s N E p L i T t DRI a VE ENTRANCE ROOSEVELT DRIVE l 900, ST2 Index 1 The Triangle Nursery 9 Old Road Campus Estates Annexe 13 Boundary Brook House Interserve Joint Research Office Kennedy Institute 2 - Research Services, Medical Sciences Division Old Road Campus Research Building 10 - Clinical Trials and Research Governance 3 New Richards Building Department of Oncology - Human Tissue Governance CRUK/MRC Oxford Institute for Radiation Oncology - Medical Sciences Division Business Development 4 NDM Research Building Institute of Biomedical Engineering Nuffield Department of Primary Care Health Sciences Target Discovery Institute Jenner Institute Medical Sciences Divisional Safety Officers Centre for Tropical Medicine and Global Health Bodleian Knowledge Centre (Library Services) Medical Sciences Division IT Services 5 Wellcome Centre for Human Genetics (WHG) Ludwig Institute for Cancer Research Structural Genomics Consortium 6 Henry Wellcome Building for Molecular Physiology Nuffield Department of Surgical Sciences Loading Bays and Delivery Offices of the Nuffield Professor of Medicine ENTRANCE VIA BUILDING 5 11 Big Data Institute A Wellcome Trust Centre for Human Genetics 7 Henry Wellcome Building for Particle Imaging
    [Show full text]
  • Astrazeneca-Oxford Vaccine Approved for Use in the U.K
    P2JW366000-6-A00100-17FFFF5178F ****** THURSDAY,DECEMBER 31,2020~VOL. CCLXXVI NO.154 WSJ.com HHHH $4.00 DJIA 30409.56 À 73.89 0.2% NASDAQ 12870.00 À 0.2% STOXX 600 400.25 g 0.3% 10-YR. TREAS. À 3/32 , yield 0.926% OIL $48.40 À $0.40 GOLD $1,891.00 À $10.50 EURO $1.2300 YEN 103.21 Deadly Attack at Airport Targets New Yemen Government U.S. IPO What’s News Market Reaches Business&Finance Record nvestorspiled into IPOs Iat a record rate in 2020, with companies raising Total $167.2 billion via 454 of- ferings on U.S. exchanges this year through Dec. 24. Few see signs of letup Few expect the euphoria after companies raise to wear off soon. A1 more than $167 billion Detenteisending in the global fight over tech taxes, despite pandemic with Franceresuming collec- tion of itsdigital-services tax BY MAUREEN FARRELL and the U.S. poised to retali- atewith tariffs.Other coun- Defying expectations,inves- tries areset to join the fray. A1 S tors piled intoinitial public of- China finished 2020 PRES feringsatarecordrateiN with a 10th consecutive TED 2020, and few expect the eu- month of expansion in its CIA phoria to wear off soon. manufacturing sector. A7 SO Companies raised $167.2 AS TheEUand China agreed TENSIONS HIGH: People fled after an explosion Wednesday at the airport in Aden, Yemen, moments after members of the billion through 454 offerings in principle on an invest- country’s newly sworn-in cabinet arrived. At least 22 people were killed, but all the members of the cabinet were safe.
    [Show full text]
  • Annual Meeting
    Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign.
    [Show full text]
  • Jenner Institute Complementary Vaccines Platform Technologies
    WHO R&D Blueprint: Janssen Vaccines – Jenner Institute complementary Vaccines Platform Technologies Janssen Vaccines: Jenner Institute: Olga Popova Prof. Sarah Gilbert Jerome Custers WHO Geneva, 21 July 2016 Background • Jenner Institute & Janssen Vaccines presented respective proposals to WHO R&D Blueprint Workshop in April 2016, and were invited to join forces for Round 2 submission • Example of alignment, coordination and partnership between public and private sector stakeholders • Understanding nature of vaccine development, established complementary end‐to‐end skills and capabilities • Long‐term, sustainable & consistent approach and funding • High‐level flexible proposal with illustrative examples • «Bona fide»: collaborative framework to be developed JOINTLY TOWARDS TANGIBLE OUTCOMES x GLOBAL PUBLIC HEALTH 2 Success factors • Available platforms and previous experience with pathogens • Ability to invest time and resources, leverage expertise, minimise opportunity costs and ensure business continuity • Appropriate and functionable operational model, speed • Lean governance, partner alignment and milestone orientation INTERNAL • Reliable & qualified partners, durable commitments • Long‐term reliable funding (min 5‐year horizon) • Resolving vaccination indemnification / liability issue • Consistency in pathogen prioritisation and defined, consistent pre‐ established endpoint commitment • Clear and accelerated / streamlined regulatory pathways, conditions & predictability of licensure EXTERNAL • Anticipated deployment plans and community
    [Show full text]
  • Sir Bryn Terfel Premieres John Rutter's 'Joseph's Carol', Dedicated to the Oxford Vaccine Team in Celebratory Concert Fr
    Sir Bryn Terfel premieres John Rutter’s ‘Joseph’s Carol’, dedicated to the Oxford vaccine team in celebratory concert from the Oxford Philharmonic Orchestra Friday 18 December 2020, 18:30 Streamed on Oxford Philharmonic Orchestra’s YouTube Channel: bit.ly/OPOVaccineTribute Elgar Chanson de Matin William Henry Monk Abide with Me Rodgers & Hammerstein You’ll Never Walk Alone John Rutter Joseph’s Carol WORLD PREMIERE John Rutter Look to the Day Handel Hallelujah Chorus Sir Bryn Terfel bass-baritone Oxford Philharmonic Orchestra Maxim Vengerov violin Choir of Merton College, Oxford John Rutter conductor Alexandra Lowe soprano Marios Papadopoulos conductor Alexander Olleson treble John Suchet presenter In recognition of the formidable work accomplished by the team of scientists at the University of Oxford on their Covid-19 vaccine, the Oxford Philharmonic Orchestra will stream a celebratory concert on Friday 18 December, recorded in the city’s historic Sheldonian Theatre. Performed by bass-baritone Sir Bryn Terfel, the short concert features the premiere of John Rutter’s Joseph’s Carol, written in tribute to the Oxford Vaccine Group, the Jenner Institute and the RECOVERY team. The words by John Rutter recount the long and weary journey of Joseph and Mary to Bethlehem before the birth of the baby Jesus, echoing the programme’s journey from struggle through to hope. Bryn Terfel also joins the Orchestra and the Choir of Merton College, Oxford, in a rousing programme from Rodgers & Hammerstein’s You’ll Never Walk Alone (with Jette Parker Young Artist Alexandra Lowe) to Handel’s Hallelujah Chorus. Sir Bryn and the Orchestra are also joined in the hymn of comfort, Abide with Me, by chorister Alexander Olleson of Christ Church Cathedral Choir, the recent winner of BBC Young Chorister Of The Year 2020.
    [Show full text]
  • Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein
    Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein By Rachel Elizabeth Owen A thesis submitted for the degree of Doctor of Philosophy at the University of London September 2003 The Edward Jenner Institute for Vaccine Research University College London ProQuest Number: U642330 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U642330 Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Hepatitis C virus establishes a persistent infection in approximately 80% of infected individuals. It is unclear why the immune system is frequently unable to mediate a response capable of controlling HCV replication. Dendritic cells (DCs) may be an extrahepatic site of viral replication and it is hypothesised that expression of the core protein within DCs may impair their functions resulting in inadequate immune responses. To investigate potential immunomodulatory effects of the core protein on DCs, replication-deficient adenoviral vectors co-expressing different versions of the core protein (full-length, truncated and a version lacking residues 125-144) with GFP were constructed. Whilst these adenoviruses were being generated, experiments were carried out with an adenoviral vector expressing all the HCV structural proteins (Ad- CE1E2).
    [Show full text]
  • 'Astrazeneca' Covid-19 Vaccine
    Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices.
    [Show full text]
  • Job Description and Person Specificationselection Criteria
    Job title Senior Postdoctoral Scientist Division Medical Sciences Department Nuffield Department of Medicine, Jenner Institute Clinical Centre for Vaccinology and Translational Medicine Location (CCVTM), Old Road Campus, Headington, Oxford, OX3 7LE Grade 8: £41,526 - £49,553 per annum with a discretionary range Grade and salary to £54,131 per annum Hours Full time Contract type Fixed-term contract for 20 months, in the first instance Reporting to Professor Christine Rollier & Professor Cal MacLennan Vacancy reference 147960 Additional Position funded by US funding information Development of a Gonococcal Outer Membrane Vesicle Vaccine Research topic from Lead Optimization to Phase 1 Clinical Trial Principal Investigator Professor Christine Rollier & Professor Cal MacLennan / supervisor Project team Gonococcal Vaccine Group http://www.jenner.ac.uk/ Project web site Funding partner US funding 1. Gottlieb SL, et al. Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 2020; 38: 4362-4373. 2. Micoli, F et al. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. PNAS 2018; Recent publications 115: 10428-33. 3. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467-478. 4. Marsay L, et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect 2015; 71: 326-37. The Role The Gonococcal Vaccine Project is based at the Jenner Institute, University of Oxford, and utilizes a novel outer membrane vesicle (OMV) technology to develop a vaccine against gonorrhoea.
    [Show full text]
  • ASTMH 65Th Annual Meeting Atlanta Marriott Marquis and Hilton Atlanta Atlanta, GA Pre-Registration List As of October 27, 2016
    ASTMH 65th Annual Meeting Atlanta Marriott Marquis and Hilton Atlanta Atlanta, GA Pre-Registration List as of October 27, 2016 *John Aaskov, PhD FRCPath Denise Abud Oladokun Adedamola Adesunloye, Queensland University of Technology Sanofi Pastuer Federal Ministry of Health(FMC) Australia USA Nigeria Neetu Abad Manfred M K Accrombessi Grace Adeya CDC Benin GHSC-PSM/Chemonics United States USA *Jane Winnie Achan, Clinical *Tochukwu Abadom MRC Unit, The Gambia Bwaka Mpia Ado Blackpool Victoria Hospital, United Gambia McKIng Consulting Corporation/ EPI Kingdom DRC Nigeria *Nicole L. Achee, PhD Dem. Republic of Congo Univ of Notre Dame *Shaymaa Abdalal, MD USA Joseph Ado-Yobo Tulane School of Public Hlth Ghana USA Salissou Adamou Bathiri Onchocerciasis & Lymphatic *Valentine Adolphe *Agatha Aboe, MBChB; DO Niger PSI Sightsavers USA Ghana *David P. Adams, PhD MPH MSc Dept of Community Medicine, Mercer Yaw Asare Afrane *Ayokunle Abogan Univ Sch of Medicine Kenya Medical Research Institute Natl Malaria Programme USA Kenya Botswana *John H. Adams, PhD Suneth Agampodi, MBBS MSc *Melanie Abongwa, MSc University of South Florida Coll of Pub Univ of Sri Lanka Iowa State University Hlth Sri Lanka USA USA *Kokila Agarwal, DRPH MBBS MPH *Ahmed Abd El Wahed Abou El Nasr, *Matthew Adams MCHIP/JHPIEGO Georg August University Goettingen Univ of Maryland Baltimore USA Germany USA Kodjovi D. Agbodjavou *Jennifer Abrahams, MD Marc Adamy Jhpiego Corp University of Miami/Jackson Memorial Medicines for Malaria Venture Togo Hospital Switzerland USA Rakesh Aggarwal, MD DM *David Addiss, MD MPH Sanjay Gandhi Postgraduate Inst of Lauren Abrams, GA Task Force for Global Hlth Med Sciences Children Without Worms USA India United States *Ahmed Adeel, MD MPH PhD *Selidji Todagbe AGNANDJI Marcelo Claudio Abril United States CERMEL Fundación Mundo Sano Gabon Argentina *Adeshina Israel Adekunle UNSW *Peter C.
    [Show full text]
  • University of Oxford Oxford OX3 7LE
    Prof Adrian Hill Centre for Clinical Vaccinology & Chief Investigator Tropical Medicine (CCVTM) The Jenner Institute Churchill Hospital University of Oxford Oxford OX3 7LE Recruitment Co-ordinator National Research Ethics Service Tel: 01865 611424 Committee: South Central Oxford A Fax: 01865 289694 Number: 17/SC/0552 Email: [email protected] PARTICIPANT INFORMATION SHEET: MERS001 A study to assess the new candidate MERS-CoV vaccine in healthy adults “A phase I study to determine the safety and immunogenicity of the candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in UK healthy adult volunteers” We would like to invite you to take part in a research study. Before you make a decision, it is important you take the time to understand why the research is being done and what it would involve. Please read the following information carefully and discuss it with friends, relatives and your General Practitioner (GP) if you wish. • Part 1 tells you the purpose of the study and what will happen to you if you take part. • Part 2 tells you more information about the conduct of the study. Please ask us if there is anything that is not clear, or if you would like more information. Take time to decide whether or not to take part. PART 1 What is the purpose of this trial? The purpose of this study is to test a new vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in healthy volunteers. MERS-CoV has been identified as one of the most worrying newly emerging outbreak diseases by many global agencies and expert groups, including the World Health Organization (WHO).
    [Show full text]
  • MALARIA VACCINES for the WORLD 2-4 May 2016, Leiden University Medical Center LUMC, Leiden, the Netherlands
    THE FOURTH INTERNATIONAL CONFERENCE ON: MALARIA VACCINES FOR THE WORLD 2-4 May 2016, Leiden University Medical Center LUMC, Leiden, The Netherlands SECOND CIRCULAR AND PROVISIONAL CONFERENCE PROGRAMME FOR MVW 2016 With more an estimated 200 million clinical cases annually, resulting in more than 580,000 deaths, malaria is not only an important global health problem but also a major factor limiting economic development in developing countries. Interventions that deploy an effective malaria vaccine are regarded as being one of the most cost-effective and reliable means to limit and ultimately eradicate the disease. In recent years, due to increased funding and research, malaria vaccine development has greatly accelerated. The MVW 2016 conference will look at different aspects of vaccine development, assessment and deployment, as well as funding and regulatory aspects of vaccine implementation and testing. The conference will also highlight research on the use of animal models and (controlled) clinical trials to study the immunological basis of protection and to identify novel candidate vaccine antigens. The MVW 2016 meeting will be of interest to scientists, physicians and other professionals from the academic, industrial/commercial and governmental/policy/regulatory sectors that have an interest in vaccine development and global health. The meeting will include talks on: Malaria vaccine candidate discovery · Novel pre-clinical screening assays/models · Vaccine immunology including system-based approaches · Correlates of protection after vaccination · Pre-erythrocytic vaccines and vaccination · Vaccines for interrupting malaria transmission: role in elimination strategies · RTS,S implementation and refinements · Vaccines against blood stage of malaria infection and multi-stage vaccines · Clinical trials of malaria vaccines controlled human malaria infections (CHMI) and field trials · Relevance and issues related to first in man trials and CHMI studies in endemic countries · Modelling and measuring long-term malaria vaccine impact.
    [Show full text]
  • Isis Insights 63
    The research commercialisation office of the University of Oxford, previously called Isis Innovation, has been renamed Oxford University Innovation All documents and other materials will be updated accordingly. In the meantime the remaining content of this Isis Innovation document is still valid. URLs beginning www.isis-innovation.com/... are automatically redirected to our new domain, www.innovation.ox.ac.uk/... Phone numbers and email addresses for individual members of staff are unchanged Email : [email protected] Ii 63 Spring 11 Issue Isis insights The latest innovations, collaborations and technology transfer Healthy futures Screening for discovery... IiContents Issue 63 Healthy futures Screening for discovery... Tackling Tuberculosis 10 Protein Superglue 26 Patient Reported Outcomes 28 03. Newsflash 18. Transformers The latest news from Isis Lightweight motor magnets 04. The Loop 20. Testing, Testing A news roundup from Oxford University Making test tube research more reliable Consulting and Isis Enterprise 22. Spring Clean 05. The Portfolio Showcasing clean-tech energy systems Investment and spin-out news 24. Fluid Thinking 06. Technology Steps Forward An acoustic separator for a wide audience The latest licence agreements 26. Protein Superglue Identifying proteins linked with diseases 08. Scouting for Success Oxford Innovation Society member Dow Chemical’s investment strategies 28. The PROs of Academic Consultancy Oxford University Consulting helping with 10. Tackling Tuberculosis healthcare A vaccine for the 21st Century 30. Above Sea Level 12. Oxford-Emergent Tuberculosis Isis Enterprise using submarine technology for Consortium Focus health screening Deeper insight into the TB vaccine partnership 16. Inside the Incubator A new initiative for Oxford software Ii is produced by Isis Innovation Ltd, the technology transfer company owned by the University of Oxford.
    [Show full text]